Navigation Links
Particle Sciences Develops Proprietary Nasal Delivery Formulation Used in Neurelis' Recently Announced Successful Phase I Pharmacokinetic Study of NRL-01 (intranasal diazepam)
Date:6/22/2011

BETHLEHEM, Pa., June 22, 2011 /PRNewswire/ -- In a recent announcement by Neurelis, a proprietary intranasal formulation of diazepam (NRL-1) achieved positive clinical results in a Phase I pharmacokinetic study.  The propriety formulation was designed and manufactured at Particle Sciences.  In the Phase 1 clinical trial NRL-1 demonstrated a pharmacokinetic profile comparable to that reported in the literature for Diastat® (rectal diazepam gel), the only FDA approved therapeutic product for home treatment of acute repetitive seizures.  The bioavailability of the NRL-1 intranasal formulation was 96%.

According to Dr. Robert Lee, Particle Sciences VP of Pharmaceutical Development, "We are obviously very pleased with the results Neurelis have obtained.  It has been a pleasure working with them and very rewarding to contribute to a product that should truly improve the quality of life for patients with acute repetitive seizures and their caregivers.  We were able to achieve extremely high levels of solubilized diazepam using our DOSE® platform that combines empirically obtained data with customized solubility software.  This approach along with Particle Sciences' cGMP analytical and manufacturing services have enabled our clients to more rapidly advance to the clinic with commercially viable formulations."

David F. Hale, Chairman of Neurelis, said that "The team at Neurelis was very pleased with the work on the formulation conducted by Particle Sciences.  They really focused on a key issue with diazepam which is solubility and developed two proprietary formulations which we evaluated in the clinical trial.  Based on the results obtained in the clinical trial we plan to move ahead with the further development of this product candidate for patients with epilepsy who have acute repetitive seizures."

Particle Sciences Inc. is an integrated provider of drug development services.  Particle Sciences utilizes a broad suite of drug delivery technologies to address a diverse range of challenges.  With special expertise in solubility, particulate based formulations and drug/device combination products, Particle Sciences has become a leader in drug delivery development.  Through a full range of formulation, analytic, bioanalytic, and sterile and non-sterile manufacturing services, Particle Sciences provides pharmaceutical companies with a complete and seamless development solution that minimizes the time and risk between discovery and the clinic.  The company was founded in 1991 and is headquartered in Bethlehem, Pennsylvania.  Visit www.particlesciences.com, email info@particlesciences.com or contact us at (610) 861-4701 for information.

Neurelis, Inc. is a San Diego-based specialty pharmaceutical company organized to license, develop, and commercialize product candidates for epilepsy and the broader central nervous system ("CNS") market.  Neurelis leverages expertise in the development and commercialization of CNS compounds and strong relationships with leading researchers and clinicians in these markets to advance unique product candidates to address significant unmet medical needs.

Contact: Maureen Cochran
mcochran@particlesciences.com
610-861-4701


'/>"/>
SOURCE Particle Sciences Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Targeted Nanoparticles Offer Promise in the Battle Against Cancer
2. IBA and Elekta Initiate Global Particle Therapy Program at ASTRO
3. Recent Findings from the Framingham Offspring Study Show Low Numbers of LDL Particles (LDL-P) by NMR are Associated With Fewer Heart Disease Related Events than Equivalently Low Levels of LDL Cholesterol (LDL-C).(1)
4. Celator(R) Pharmaceuticals Successfully Uses Nanoparticles to Administer Hydrophobic Drug Combinations
5. Ion Mobility Diagnostic Test from Quest Diagnostics is First to Provide Direct Physical Measurement of Lipoprotein Particles, Cardiovascular Disease Indicators, Study Finds
6. Particle Sciences Expands Its Combination Product Capabilities
7. Novavax Reports Positive Preclinical Results for a Novel, Broadly Cross-Protective H5N1 Pandemic Influenza Virus-like Particle (VLP) Vaccine Candidate
8. Particle Sciences and IES Engineers Cooperate on High Potency Compound Handling Capabilities
9. MicroConstants Now Offers Nanoparticle Formulation Services
10. ChemImages Raman Chemical Imaging Used for Ingredient-Specific Particle Sizing for Inhalation Product Development
11. Varian Medical Systems Introduces ProBeam(TM) Proton Therapy Platform at Particle Therapy Co-operative Group (PT COG) 2010 Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... and SAN CLEMENTE, Calif. , June 24, ... -based mobile pulmonary function testing company, is now able to perform ... developed by ndd Medical Technologies , Inc. ... in hospital-based labs.  Thanks to ndd,s EasyOne PRO ® , ARL ... can get any needed testing done in the comfort of her ...
(Date:6/24/2016)... Belgium , June 24, 2016 ... the appointment of Dr. Edward Futcher ... Non-Executive Director, effective June 23, 2016.Dr. Futcher was ... Nominations and Governance Committees.  As a non-executive member ... independent expertise and strategic counsel to VolitionRx in ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... , ... On June 10-11, 2016, A Forever Recovery, a holistic treatment center ... Breakfast Table in Battle Creek, MI, where the rehabilitation facility is located. This annual ... the world’s leading providers of cereal and other breakfast foods. Its residents often refer ...
(Date:6/25/2016)... ... 25, 2016 , ... Experts from the American Institutes for ... Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR ... care planning, healthcare costs and patient and family engagement. , AIR researchers will ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... San Francisco, CA (PRWEB) , ... June 24, ... ... at CitiDent, is now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has ... , self-ligating Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , ...
Breaking Medicine News(10 mins):